Medicaid Fraud Scorecard

Pharma's $2 billion in payouts since 2000 to settle claims of fraudulent Medicaid-related marketing and pricing practices has left the industry in flux, as it seeks to determine the kinds of packages and programs that will pass government muster. It appears that the strength of many current and presumed future fraud cases will be based on establishing a company's reasonable foreknowledge of the activities of its customers, with the argument even extended to gray areas including improper encouragement of off-label drug usage and the development of data to support those uses--issues that will affect device companies at least as much as Pharma.

Since 2000, drug companies have paid out $2 billion to settle claims of fraudulent Medicaid-related marketing and pricing practices. Factoring in other fines and penalties, the dollar total rises to more than $3.5 billion--the vast bulk of all the monies paid out under the US False Claims Act. From 2000 to January 2004, eight of the top ten cases resolved under the False Claims Act, which encourages whistleblowers by allowing private citizens to sue on behalf of the government and receive a share of any awards, involved companies in the health care space.

The result is an industry whose marketing practices are in flux, as it tries to determine the kinds of packages...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Leadership

More from In Vivo